Bad behavior may be the result of a treatable condition
called canine separation anxiety

When dogs become upset by their owner’s absence, the stress can lead to abnormal behaviors, such as excessive barking, chewing, clawing or house soiling. These behaviors could indicate a clinical condition called canine separation anxiety. Up to 17% of dogs in the United States may be affected by separation anxiety.1

Developed for dogs, Reconcile (fluoxetine hydrochloride) is a once-daily chewable tablet indicated for the treatment of canine separation anxiety in conjunction with a behavior modification plan. Prescribed by veterinarians, Reconcile is approved by the FDA for use in dogs 6 months or older. Combined with training, Reconcile reduces the frequency of separation anxiety behaviors, which enables dog owners to enjoy the positive emotional connection they want with their pet.

Label information

Important Safety information

  • The most common adverse events reported in decreasing order of reported frequency are: decreased appetite, depression/lethargy, shaking/shivering/tremor, vomiting, restlessness and anxiety, seizures, aggression, diarrhea, mydriasis, vocalization, weight loss, panting, confusion, incoordination and hypersalivation.
  • Reconcile chewable tablets are contraindicated for dogs with epilepsy or a history of seizures; with drugs that lower the seizure threshold; with a monoamine oxidase inhibitor (MAOI) or within a minimum of 14 days of discontinuing therapy with an MAOI; in dogs with a known hypersensitivity to fluoxetine HCl or other SSRIs.
  • A six-week washout interval should be observed following discontinuation of therapy with Reconcile chewable tablets prior to the administration of any drug that may adversely interact with fluoxetine or norfluoxetine.
  • For full product label, including complete safety information, click here.

1. Elanco Market Research with Veterinarians and Veterinarian Technicians. 2006.

CAH1347

For Material Safety Data Sheet (MSDS) contact 888-545-5973